RPG Life Sciences Q1 FY27: Revenue ₹195.7 Cr, PAT ₹30.8 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹196Cr
- +16% YoY
- +10.7% QoQ
- Net profit
- ₹31Cr
- +19.2% YoY
- +3.3% QoQ
- Margin
- 22%
- +1 pp YoY
- +3 pp QoQ
Guidance rank: #80 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on RPG Life Sciences Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] - Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18] - Q1 FY27 PAT: ₹30.8 EBITDA: ₹41.5 crores in Q1 FY27, up 17.0% from ₹35.4 crores in Q1 FY26 - EBITDA Margin: 21.2% in Q1 FY27, slightly up from 21.0% in Q1 FY26 - Revenue from Operations: ₹195.7 crores in Q1
From RPG Life Sciences Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18]
- Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18]
- Q1 FY27 PAT: ₹30.8 crores, up 17.0% YoY (Q1 FY26: ₹26.3 crores) [Page 18]
- Domestic Formulations sales: ₹132.5 crores, up 14.8% YoY (Q1 FY26: ₹115.4 crores) [Page 19]
2 more points from RPG Life Sciences Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what RPG Life Sciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rs 185+ crores capex infused since FY22 to build a modern, state-of-the-art plant with approvals from EU, TGA, PMDA, etc. (Page 24)
- Evaluation ongoing for varied opportunities to improve manufacturing productivity (Page 24)
- Ankleshwar multipurpose formulation plant equipped for low humidity products serving domestic and emerging markets; strong production capacity (Page 8)
- API manufacturing facility in Navi Mumbai with three units including a dedicated immunosuppressant unit, catering to regulated markets (Page 8)
2 more points from RPG Life Sciences Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what RPG Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what RPG Life Sciences Ltd said on order book & pipeline — free account, 30 seconds.
RPG Life Sciences Ltd — Quarterly revenue & net profit
RPG Life Sciences Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 196 | 169 | +16% | 177 | +10.7% |
| Operating profit (EBITDA) | 44 | 35 | +25.7% | 33 | +33.3% |
| Operating margin | 22% | 21% | +1 pp | 19% | +3 pp |
| Profit before tax | 41 | 35 | +17.1% | 40 | +2.5% |
| Net profit (PAT) | 31 | 26 | +19.2% | 30 | +3.3% |
| EPS (₹) | 18.49 | 15.90 | +16.3% | 18.08 | +2.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹212 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What RPG Life Sciences's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q2 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
RPG Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were RPG Life Sciences Ltd Q1 FY27 results?
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] - Q1 FY27 EBITDA: ₹48.0 crores, up 17.9% YoY (Q1 FY26: ₹40.7 crores) [Page 18] - Q1 FY27 PAT: ₹30.8 EBITDA: ₹41.5 crores in Q1 FY27, up 17.0% from ₹35.4 crores in Q1 FY26 - EBITDA Margin: 21.2% in Q1 FY27, slightly up from 21.0% in Q1 FY26 - Revenue from Operations: ₹195.7 crores in Q1
What is RPG Life Sciences Ltd share price analysis?
RPG Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of 39.7 with a market cap of ₹4,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is RPG Life Sciences Ltd planning capital expenditure?
Rs 185+ crores capex infused since FY22 to build a modern, state-of-the-art plant with approvals from EU, TGA, PMDA, etc.
Keep RPG Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
